Velasco Cimica, Ph.D., is an expert in vaccine development using virus-like particles for developing vaccine candidates for emerging viruses. Join this webinar to hear Dr. Cimica cover the following key points:
- We have developed a chimeric Zika-VLP–based vaccine that elicits a protective immune response and prevents antibody-dependent enhancement (ADE) and Guillian Barré Syndrome (GBS) in murine animal models.
- Zika-VLPs containing the CD loop sub-structural domain from envelope protein domain III induced a strong antibody response against the Zika virus in mouse models after prime immunization.
- The protective immunity of our novel Zika-VLP vaccine candidates is mediated by antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.